Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury

Brain Injury

Volumn 13, Issue 12, 1999, Pages 1025-1031

  Wilkinson, Robert ^a   Meythaler, Jay M ^a   Guin Renfroe, Sharon ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PROPRANOLOL;

ADOLESCENT; AGITATION; ARTICLE; BRAIN INJURY; CASE REPORT; DAILY LIFE ACTIVITY; DECEREBRATION; DIAPHORESIS; DOPAMINE RELEASE; DRUG WITHDRAWAL; DYSTONIA; FEVER; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPSYCHOLOGY; SYMPTOM; TACHYCARDIA;

EID: 0032724164     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/026990599121034     Document Type: Article

References (48)

1. INTERAGENCY HEAD INJURY TASK FORCE: Report, National Institute of Neurological Disorders and Stroke, National Institutes of Health. Bethesda, MD, February 1989.
2. ADAMS, J. H., MITCHELL, D. E., GRAHAM, D. I. et al.: Diffuse brain damage of immediate impact type: Its relationship to primary brain-stem damage in head injury. Brain, 100: 489-502, 1977.
3. ADAMS, J. H., DOYLE, D., FORD, I. et al.: Diffuse axonal injury in head injury: Definition, diagnosis and grading. Histopathology, 15: 459, 1989.
4. MCLELLAN, D. R.: The structural bases of coma and recovery: Insights from brain injury in humans and experimental animals. Physical Medicine Rehabilitation Reviews, 4: 389-407, 1990.
5. POVLISHOCK, J. T.: Pathobiology of traumatically induced axonal injury in animals and man. Annals of Emergency Medicine, 22: 980-986, 1993.
6. MCINTOSH, T. K., VINK, R., SOARES, H. et al.: Effects of N-Methyl-D-Aspartate receptor blocker MK-801 on neurologic function after experimental brain injury. Journal of Neurotrauma, 6: 247-259, 1989.
7. LINDSAY, K. W., BONE, I. and CALLENDER, R.: Neurology and Neurosurgery Illustrated, 2nd Edn (New York: Churchill Livingstone), pp 141-199, 1991.
8. EVANS, R. W. and GUALTIERI, C. T.: Psychostimulant pharmacology in traumatic brain injury. Journal of Head Trauma Rehabilitation, 2: 29-33, 1987.
9. ROSS, E. D. and STEWART, R. M.: Akinetic mutism from hypothalamic damage: Successful treatment with dopamine agonist. Neurology, 31: 1435-1439, 1981.
10. WHYTE, J. and ROSENTHAL, M.: Rehabilitation of the patient with traumatic brain injury. In J. A. DeLisa (editor) Rehabilitation Medicine: Principles and Pratice, 2nd Edn (Philadelphia: Lippincott Company), pp. 825-860, 1993.
11. AUERBACH, S. H.: Neuroanatomical correlates of attention and memory disorders in traumatic brain injury: An application of behavioral subtypes. Journal of Head Trauma Rehabilitation, 1: 1-12, 1986.
12. CARDENAS, D. D. and MCLEAN, JR. A.: Psychopharmacolgic management of traumatic brain injury. Physical Medicine and Rehabilitation Clinics of North America, 3: 273, 1992.
13. FEENEY, D. M., GONZALEZ, A. and LAW, W. A.: Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex surgery. Science, 217: 855-857, 1982.
14. VAN HASSELT, P.: Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology, 12: 245-247, 1973.
15. DELAY, J., PICOT, P., LEMPERIER, M. T. et al. Un neuroleptique majeur non phenothiazineque et non reserpinique, l'halidol, dans le traitement des psychoses. Annals of Medical Psychology (Paris), 118: 145-152, 1960.
16. BOURGEOIS, M., TIGNOL, J. and DEBOUCHARD, D.: Le syndrome malin des neuroleptiques. Bordeaux Medicine, 4: 1115-1128, 1971.
17. KELLAM, A. M.: The neuroleptic malignant syndrome, so-called - a survey of the world literature. British Journal of Psychiatry, 150: 752-759, 1987.
18. MYERS, F. H.: Benign type of malignant syndrome. Lancet, I: 50, 1989.
19. KELLUM, A. M. P.: The (frequently) neuroleptic (potentially) malignant syndrome. British Journal of Psychiatry, 157: 16-17, 1990.
20. BRISTOW, M. F. and KOHEN, D.: How 'malignant' is the neuroleptic malignant syndrome? British Medical Journal, 307: 1223-1224, 1993.
21. CAROFF, S. N. and MANN, S. C.: Neuroleptic malignant sydrome. Medical Clinics of North America, 71: 185-202, 1993.
22. SHALEV, A. and MUNITZ, H.: The neuroleptic malignant syndrome: Agent and host interation. Acta Psychiatrica Scandinavica, 73: 337-347, 1986.
23. GELENBERG, A. J., BELLINGHAUSEN, B., WOJCIK, J. D. et al.: A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. American L Psychiatry, 145: 517-518, 1988.
24. KECK, P. E., POPE, H. G. and MCELROY, S. I.: Declining frequency of neuroleptic malignant syndrome in a hospital population. American Journal of Psychiatry, 148: 880-882, 1991.
25. HENDERSON, V. W. and WOOTEN, G. F.: Neuroleptic malignant syndrome: A pathophysiologic role for the dopamine receptor blockade? Neurology, 1331: 1495-1497, 1981.
26. KECK, P. E., POPE, H. G., COHEN, B. M. et al.: Risk factors for neuroleptic malignant syndrome. Archives of General Psychiatry, 46: 914-918, 1989.
27. ROSEBUSH, P. I. and STEWART, T. A.: Prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146: 717-725, 1989.
28. ADAMS, R. D. and VICTOR, M.: Principles of Neurology, 5th Edn (New York: McGraw-Hill Inc), pp. 934-935, 1993.
29. Diagnostic and Statistical Manual for Mental Disorders. 4th edn (DSM-IV) (Washington DC: American Psychiatric Press), pp. 739-742, 1994.
30. BAREGGI, S. R. et al.: HVA and %-HIAA in CSF of patients after severe head injury syndrome. European Neurology, 13: 528-544, 1975.
31. KRAUS, M. F. and MAKI, P.: The combined use of Amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Injury, 11: 455-460, 1997.
32. VAN WOERKUM, T. C. A. M., TEELKEN, A. W. and MEINDERHOUD, J. M.: Difference in neurotransmitter metabolism in frontotemporal-lobe contusion and diffuse cerebral contusion. Lancet, 1: 812-813, 1977.
33. VAN WOERKOM, M.: Pharmacologic Interventions. PM&R Reviews, 4: 447-464, 1990.
34. SNYDER, S. H., GREENBERG, D. and YAMANURA, H.: Anti-schizophrenic drugs and brain cholinergic receptors. Archives of General Psychiatry, 31: 58-61, 1974.
35. ADELOY, A.: Clinical trial of fluphenazine in the postconcussional syndrome. Practioner, 206: 517-519, 1971.
36. VASCONCELLOS, J.: Clinical evaluation of trifluoperazine in maximum-security brain damaged patients with an organic brain disorder. JAMA, 240: 380-382, 1978.
37. KAPLAN, H. I. and SADOCK, B. J. (editors) Pocket Handbook of Psychiatric Drug Treatment: dopamine receptor antagonist: antipsychotics (Baltimore: Williams and Wilkins), pp. 104-131, 1993.
38. REINHARD, M., DOUGHTERY, A. and SANDEL, M.: Improved arousal and initiation following tricyclic antidepressant use in traumatic brain injury. Archives of Physical Medicine & Rehabilitation, 77: 80-83, 1996.
39. KAELIN, D., WHYTE, J. and SANDEL, M.: Methylphenidate effect on attention deficit in the acutly brain injured adult study. Archives of Physical Medicines & Rehabilitation, 77: 6-9, 1996.
40. PLENGER, P.: Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double blind study. Archives of Physical Medicine & Rehabilitation, 77: 536-540, 1996.
41. SAKKAS, P., DAVIS, J. M., HUA, J. et al.: Pharmacotherapy of neuroleptic malignant syndrome. Psychiatry Annals, 21: 157-164, 1991.
42. MOONEY, R. P. and HASAN, M. K.: Neuroleptic malignant syndrome. W V Medical Journal, 86: 95-98, 1990.
43. BROOKE, M. M., PATTERSON, D. R., QUESTAD, K . A. et al.: The treatment of agitation during initial hospitalization after traumatic brain injury. Archives of Physical Medicine & Rehabilitation. 73: 917-921, 1992.
44. MEYTHALER, J. M. and STINSON, A. M.: Fever of central origin in traumatic brain injury controlled with propanolol. Archives of Physical Medicine & Rehabilitation, 75: 816-818, 1994.
45. VAN REEKUM, R.: N of 1 study; Amantadine for a motivational syndrome in a patient with traumatic brain injury. Brain Injury, 9: 49-53, 1995.
46. NICKELS, J., SCHNIEDER, W., DOMBROVY, M. et al.: Clinical use of Amantadine in brain injury rehabilitation. Brain Injury, 8: 809-818, 1994.
47. ZAFONTE, R. D., WATANABE, T. and MANN, N. R.:Amantadine: A potential treatment for the minimally conscious state. Brain Injury, 12: 617-621, 1998.
48. VAN HASSELT, P.: Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology, 12: 245-247, 1973.